Viridian Therapeutics, Inc.

General Information

Company Name

Founded Year

2007

Location (Offices)

Waltham, United States +2

Founders / Decision Makers

Number of Employees

163

Industries

Biotechnology, Health Care, Health and Wellness

Funding Stage

Post Ipo Equity

Social Media

Viridian Therapeutics, Inc. - Company Profile

Viridian Therapeutics, Inc. is a biotechnology company dedicated to engineering medicines that address the unmet needs of patients suffering from serious diseases. The company's slogan, "Engineering Medicines To Improve Patient Care," reflects its commitment to innovative solutions. Viridian's flagship program, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody designed to treat thyroid eye disease (TED). Founded in 2007 and headquartered in Waltham, Massachusetts, Viridian operates within the Biotechnology and Health Care industries. In a recent development, the company secured a substantial $150.00M Post-IPO Equity investment on 17 January 2024, signaling confidence from the investment community in Viridian's mission and potential. This investment injects capital into the company's efforts to advance novel therapies and further its research and development initiatives. With a focus on addressing the unmet medical needs of patients, Viridian Therapeutics is poised to make significant contributions to the biotechnology and healthcare sectors.

Taxonomy: medicine, pharmaceuticals, clinical-stage, monoclonal antibody, thyroid eye disease, disease treatment, IGF-1R, Waltham, Massachusetts, startup, investor

Funding Rounds & Investors of Viridian Therapeutics, Inc. (13)

View All

Funding Stage	Amount	No. Investors	Date
Post-IPO Equity	$150.00M	-	17 Jan 2024
Post-IPO Equity	$185.00M	-	30 Oct 2023
Post-IPO Debt	$75.00M	1	04 Apr 2022
Post-IPO Equity	$85.00M	-	21 Sep 2021
Post-IPO Equity	$91.00M	-	06 Nov 2020